Imperial Innovations led the Series A round, which also included contributions form Astellas Venture Management and founding seed investor Sofinnova Partners.
Crescendo is currently developing programmes to deal with inflammation and oncology.
EMBL Ventures partner Peter Pack said, “Crescendo has established a pre-eminent position in antibody fragment technology through a unique combination of features including in vivo maturation, diversity of the immune response, unprecedented expression yields, and a plug & play modularity based on fully human Ig sequences.
“With its first programmes advancing towards the clinic, the company is in an extremely strong position to benefit from its ability to generate highly differentiated therapeutics.”
Copyright © 2014 AltAssets